{
    "title": "How Abortion Bans Will Stifle Health Care Innovation",
    "meta_title": "",
    "description": "Investment in what is typically called \u201cFemTech\u201d \u2013 defined as diagnostic tools, products, and services related to women\u2019s health \u2014 has exploded over the past decade. Some of the most promising ventures have been focused on reproductive care. Then came the U.S. Supreme Court\u2019s decision to overturn Roe v. Wade. The legal and policy restrictions on reproductive health care that result from this decision will not only have swift impact on people who can get pregnant and their families, it will also undermine critical areas of research, innovation, and progress toward more equitable health care outcomes. Among the areas of concern: fertility treatments like IVF; personal data collection and the ability to drive research; a limiting of new investment and curbing of health care innovation more broadly; and the introduction of new obstacles for women founders.",
    "meta_description": "",
    "text_headers": "Your Cart\n\n\t\t\t\tHow Abortion Bans Will Stifle Health Care Innovation\n\t\t\t\nPartner Center\nExplore HBR\nHBR Store\nAbout HBR\nManage My Account\nFollow HBR",
    "text": "\n\n\n\n\n\n\n\n\n\nHow Abortion Bans Will Stifle Health Care Innovation\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNavigation Menu\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubscribe\n\n\n\n\n\nSign In\n\n\n\n\n\nAccount Menu\n\n\n\n\n\nAccount Menu\n\n\n\n\t\t\t\t\tHi,\u00a0Guest\n\n\n\n\n\n\n\nSearch Menu\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nClose menu\n\n\n\n\n\n\n\n\n\n\n\nSearch\n\nCLEAR\n\n\n\n\n\n\n\n\n\n\nSUGGESTED TOPICS\n\n\n\n\n\n\n\n\n\n\n\nExplore HBR\n\nLatest\nThe Magazine\nAscend\nPodcasts\nStore\nWebinars\nNewsletters\n\n\n\nPopular Topics\n\nManaging Yourself\nLeadership\nStrategy\nManaging Teams\nGender\nInnovation\nWork-life Balance\nAll Topics\n\n\n\nFor Subscribers\n\nThe Big Idea\nData & Visuals\nReading Lists\nCase Selections\nHBR Learning\n\n\nSubscribe\n\n\n\n\n\nMy Account\n\nMy Library\nTopic Feeds\nOrders\nAccount Settings\nEmail Preferences\nLog Out\nSign In\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubscribe\n\nLatest\nPodcasts\nThe Magazine\nAscend\nStore\nWebinars\nNewsletters\nAll Topics\nThe Big Idea\nData & Visuals\nReading Lists\nCase Selections\nHBR Learning\nMy Library\nAccount Settings\nLog Out\nSign In\n\n\n\n\n\n\n\n\n\n\n\n\nYour Cart\n\nYour Shopping Cart is empty.\nVisit Our Store\n\n\n\n\n\n\n\n\n\n\n\nGuest User\n\n Subscriber\n\t\t\t\t\n\n\nMy Library\nTopic Feeds\nOrders\nAccount Settings\nEmail Preferences\nLog Out\n\n\n\n\n\n\nReading List\n\n\n\n\n\nReading Lists\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\t\t\tHealth care and treatment\n\t\t\n\n\n\n\t\t\t\tHow Abortion Bans Will Stifle Health Care Innovation\n\t\t\t\n\n\nInvestment in FemTech \u2014 diagnostic tools, products, and services related to women\u2019s health \u2014 has exploded over the past decade. The Dobbs decision threatens its future.\n\t\t\nby \n\nKrys Mroczkowski,\nColleen Ammerman,\n and \nRembrand Koning\n\n\n\n\n\nby \n\nKrys Mroczkowski,\nColleen Ammerman,\n and \nRembrand Koning\n\n\n\n\tAugust 08, 2022\n\n\n\n\n\n\n\n\n\n\nHBR Staff/DNY59/Getty Images\n\n\n\n\n\n\n\n \n\n\n\nPost\n\n\n\n\n \n\n\n\nPost\n\n\n\n\n \n\n\n\nShare\n\n\n\n\n \n\n\n\nAnnotate\n\n\n\n \n\n\n\nSave\n\n\n\n\n \n\n\n\nGet PDF\n\n\n\n\n \n\n\n\nBuy Copies\n\n\n\n\n \n\n\n\nPrint\n\n\n\n\n\nSummary.\u00a0\u00a0\u00a0\nInvestment in what is typically called \u201cFemTech\u201d \u2013 defined as diagnostic tools, products, and services related to women\u2019s health \u2014 has exploded over the past decade. Some of the most promising ventures have been focused on reproductive care. Then came the U.S. Supreme Court\u2019s decision to overturn Roe v. Wade. The legal and policy restrictions on reproductive health care that result from this decision will not only have swift impact on people who can get pregnant and their families, it will also undermine critical areas of research, innovation, and progress toward more equitable health care outcomes. Among the areas of concern: fertility treatments like IVF; personal data collection and the ability to drive research; a limiting of new investment and curbing of health care innovation more broadly; and the introduction of new obstacles for women founders.\n\n\n\n\n\n\n\n\n \n\n\n\nPost\n\n\n\n\n \n\n\n\nPost\n\n\n\n\n \n\n\n\nShare\n\n\n\n\n \n\n\n\nAnnotate\n\n\n\n \n\n\n\nSave\n\n\n\n\n \n\n\n\nGet PDF\n\n\n\n\n \n\n\n\nBuy Copies\n\n\n\n\n \n\n\n\nPrint\n\n\n\n\n\n\nGrowth in what is typically called \u201cFemTech\u201d \u2014 defined as diagnostic tools, products, and services related to women\u2019s health \u2014 has exploded over the past decade. As recently as 2013, less than $200 million was being invested in the field, but funding reached $2.5 billion in 2021, with projections predicting a continued ascent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nRead more on Health care and treatment\n              or related topics\n                      Start-ups,\n                      Entrepreneurship\n                      and Gender\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKrys Mroczkowski is the Associate Director for the Harvard Business School Health Care Initiative.\n\t\t\t\t\t\n\n\n\n\n\n\n\n\n\nColleen Ammerman is the director of the Race, Gender & Equity Initiative at Harvard Business School and the coauthor, with Boris Groysberg, of Glass Half-Broken: Shattering the Barriers That Still Hold Women Back at Work (Harvard Business Review Press, 2021).\n\t\t\t\t\t\n\n\n\n\n\n\n\n\n\nRembrand Koning is an Assistant Professor at Harvard Business School and the co-founder of Harvard\u2019s Tech for All Lab.\n\t\t\t\t\t\n\n\n\n\n\n\n\n \n\n\n\nPost\n\n\n\n\n \n\n\n\nPost\n\n\n\n\n \n\n\n\nShare\n\n\n\n\n \n\n\n\nAnnotate\n\n\n\n \n\n\n\nSave\n\n\n\n\n \n\n\n\nGet PDF\n\n\n\n\n \n\n\n\nBuy Copies\n\n\n\n\n \n\n\n\nPrint\n\n\n\n\n\n\n\nRead more on Health care and treatment\n              or related topics\n                      Start-ups,\n                      Entrepreneurship\n                      and Gender\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPartner Center\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLatest\nMagazine\nAscend\nTopics\nPodcasts\nStore\nThe Big Idea\nData & Visuals\nCase Selections\nHBR Learning\n\n\n\n\n           Subscribe            Explore HBR    The Latest All Topics Magazine Archive The Big Idea Reading Lists Case Selections   Podcasts Webinars Data & Visuals My Library Newsletters HBR Press HBR Ascend     HBR Store    Article Reprints Books Cases Collections Magazine Issues HBR Guide Series HBR 20-Minute Managers HBR Emotional Intelligence Series HBR Must Reads Tools     About HBR    Contact Us Advertise with Us Information for Booksellers/Retailers Masthead Global Editions Media Inquiries Guidelines for Authors HBR Analytic Services Copyright Permissions     Manage My Account    My Library Topic Feeds Orders Account Settings Email Preferences Account FAQ Help Center Contact Customer Service     Follow HBR    Facebook          X Corp.   LinkedIn  Instagram  Your Newsreader             About Us Careers Privacy Policy Cookie Policy Copyright Information Trademark Policy Terms of Use  Harvard Business Publishing:  Higher Education Corporate Learning Harvard Business Review Harvard Business School  Copyright \u00a9  \u00a0 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.         \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n"
}